by Maria Zannes | Mar 13, 2026 | Press Releases
Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company’s high-value CyPath® Lung test Number of CyPath® Lung tests performed in 2025 increased by 99% compared to 2024 Orders for CyPath® Lung by physicians and...
by Maria Zannes | Mar 10, 2026 | Press Releases
Study to evaluate clinical performance of CyPath® Lung for the early detection of lung cancer in high-risk patients Murtha Cancer Center Research Program at Uniformed Services University of the Health Sciences provides support for longitudinal study SAN ANTONIO, TX...
by Maria Zannes | Mar 3, 2026 | Press Releases
Poster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology (AAAI) Annual Meeting Research demonstrates the technology’s ability to identify drug antibody receptors in sputum for two leading asthma...
by Maria Zannes | Feb 25, 2026 | Press Releases
Validating sample collection by deep suction has potential to accelerate and expand adoption of CyPath® Lung SAN ANTONIO, TX – February 25, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and...
by Maria Zannes | Feb 19, 2026 | Press Releases
CyPath® Lung test supported recommendation for surveillance strategy, rather than subjecting elderly patient to an invasive, risky and costly biopsy procedure Despite a suspicious nodule during a low-dose CT scan, a repeat scan showed no nodules in the lungs,...
by Maria Zannes | Feb 17, 2026 | Press Releases
Noninvasive CyPath® Lung test has shown 92% sensitivity, 87% specificity and 88% accuracy for detecting lung cancer in small nodules less than 2 centimeters Case study highlights how CyPath® Lung reduces patient anxiety and supports physician confidence in assessment...
